Oxcarbazepine

The Treatment of Epilepsy: Third Edition

Volumn , Issue , 2009, Pages 575-584

  Faught, Edward ^a   Limdi, Nita ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adjunctive therapy versus placebo; Interactions between antiepileptic drugs (AEDs) and oxcarbazepine; Monotherapy in refractory patients; Non epilepsy indications; Oxcarbazepine; Oxcarbazepine efficacy in controlled clinical trials; Oxcarbazepine for partial onset seizure treatment; Pharmacokinetics in special groups

Indexed keywords

EID: 84872086940     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444316667.ch45     Document Type: Chapter

References (57)

1. Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 2004; 5: 627-635.
2. Novartis Pharmaceuticals Corporation. Trileptal (oxcarbazepine) package insert. East Hanover, New Jersey, 2007. Accessed at www.pharma.us.novartis.com/product/pi/pdf/trileptal on 30 April 2008.
3. Faigle JW, Menge GP. Pharmacokinetics and metabolic features of oxcarbazepine and their clinical significance: comparison with carbamazepine. Int Clin Psychopharmacology 1990; 5(Suppl. 1): 73-82.
4. White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol 2007; 81: 85-110.
5. Clinckers R, Smoders I, Maws A, et al. Hippocampal dopamine and serotonin elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine. Neurosci Lett 2005; 390: 48-53.
6. Augusteijn R, van Parys JAP. Oxcarbazepine (Trileptal, oxcarbazepine)-drug concentration relationship in patients with epilepsy. Acta Neurol Scand 1990; 82(Suppl. 133): 37.
7. Patsalos PN, Elyas AA, Zakrzewska JM. Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxy carbazepine in patients with trigeminal neuralgia. Eur J Clin Pharmacol 1990; 39: 413-415.
8. Dickinson RG, Hooper WD, Dunstan PR, et al. First dose and steadystate pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. Eur J Clin Pharmacol 1989; 37: 69-74.
9. Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in pediatric patients. II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine, felbamate. Clin Pharmacokinet 1995; 29: 341-369.
10. Van Heiningen P, Malcolm D, Oosterhuis B, et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991; 50: 410-419.
11. Christensen J, Sabers A, Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology 2006; 67: 1497-1499.
12. Mazzucchelli I, Onat FY, Ozkara C, et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia 2006; 47: 504-509.
13. Cloyd JC, Remmel RP. Antiepileptic drug pharmacokinetics and interactions: impact on the treatment of epilepsy. Pharmacotherapy 2000; 20(Suppl. 2): S139-S151.
14. Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994; 35(Suppl. 3): S14-S19.
15. Sonnen AE. (1990) Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 1990; 82(Suppl. 133): S34-S37.
16. Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999; 40: 783-787.
17. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239-1276.
18. Perucca E. Clinically relevant drug interactions. Br J Clin Pharmacol 2006; 61: 246-255.
19. Reinikainen KJ, Keranen T, Halonen T, et al. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987; 1: 284-289.
20. Gonzalez-Esquivel DF, Ortego-Gavilan M, Alcantara-Lopez G, Jung-Cook H. Plasma level monitoring of oxcarbazepine in epileptic patients. Arch Med Res 2000; 31: 202-205.
21. Houtkooper MA, Lammertsma A, Meyer JW, et al. Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine? Epilepsia 1987; 28: 693-698.
22. Dam M, Ekberg R, Loyning Y, Waltimo O, Jacobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70-76.
23. Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27: 195-204.
24. Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997; 27: 205-213.
25. Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26: 451-460.
26. Coppola G, Franzoni E, Verotti A, et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial. Brain Dev 2006; 29: 281-284.
27. Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: double-blind randomized, placebo-controlled, monotherapy trial for partial seizures. Neurology 1999; 52: 732-737.
28. Sachdeo R, Edwards K, Hasegawa H, et al. Safety and efficacy of oxcarbazepine 1200 mg/day in patients with recent onset partial epilepsy. Neurology 1999; 52(Suppl. 2): A391.
29. Beydoun A, Sachdeo RC, Rosenfeld WE, et al. Oxcarbazepine monotherapy for partial onset seizures: a multicenter, double-blind, clinical trial. Neurology 2000; 54: 2245-2251.
30. Sachdeo RC, Beydoun A, Schachter SC, et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology 2001; 57: 864-870.
31. Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000; 41: 1597-1607.
32. Glauser TA, Nigro M, Sachdeo R, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology 2000; 54: 2237-2244.
33. Pina-Garza JE, Espinoza R, Nordli D, et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology 2005; 65: 1370-1375.
34. Gelisse P, Genton P, Kuate C, Pesenti A, Baldy-Moulinier M, Crepel A. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 2004; 45: 1282-1286.
35. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblended randomised controlled trial. Lancet 2007; 369: 1000-1015.
36. Raju GP, Sarco DP, Poduri A, et al. Oxcarbazepine in children with nocturnal frontal-lobe epilepsy. Pediatr Neurol 2007; 37: 345-349.
37. Sachdeo RC, Gates JR, Bazil CW, et al. Improved quality of life in patients with partial seizures after conversion to oxcarbazepine monotherapy. Epilepsy Behav 2006; 9: 457-463.
38. Rainesalo S, Peltola J, Auvinen A, Keranen T. Retention rate of oxcarbazepine monotherapy in an unselected population of adult epileptics. Seizure 2005; 14: 72-74.
39. Beydoun S, Alarcon F, Mangat S, Wan Y. Long-term safety and tolerability of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand 2007; 115: 284-288.
40. Wagner KD, Kowatch RA, Emslie GJ, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006; 163: 1179-1186.
41. Aikia M, Kalviainen R, Sivenius J, et al. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow up. Epilepsy Res 1992; 11: 199-203.
42. Saber A, Moller A, Dam M. Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neurol Scand 1995; 92: 19-27.
43. Donati F, Gobbi G, Campistol J, et al. The cognitive effects of oxcarbazepine versus carbamazepine or valproate in newly diagnosed children with partial seizures. Seizure 2007; 16: 670-679.
44. Dam M, Jacobsen K. Oxcarbazepine in patients hypersensitive to carbamazepine. Acta Neurol Scand 1984; 70: 223.
45. Dogan EA, Usta BE, Bilgen R, et al. Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Epilepsy Behav 2008; 13: 156-161.
46. Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005; 65: 1976-1978.
47. Sachdeo RC, Wasserstein A, Mesenbrink PJ, D'Souza J. Effects of oxcarbazepine on sodium concentration and water handling. Ann Neurol 2002; 51: 613-620.
48. Isojarvi JIT, Huuskonen VEJ, Pakarinen AJ, et al. The regulation of serum sodium after replacing carbamazepine with oxcarbazepine. Epilepsia 2001; 42: 741-745.
49. Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 2006; 47: 510-515.
50. Gaily E, Granstrom M-J, Liukkonen E. Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability. J Int Dis Res 1998; 42(Suppl. 1): 41-45.
51. Kutluay E, McCague K, D'Souza J, Beydoun A. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav 2003; 4: 175-180.
52. Montouris G. Safety at the newer antieliptic drug oxcarbazepine during pregnancy. Curr Med Res Opin 2005; 21: 693-701.
53. Smith PEM, for the UK Oxcarbazepine Advisory Board. Clinical recommendations for oxcarbazepine. Seizure 2001; 10: 87-91.
54. Schmidt D, Sachdeo R. Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use. Epilepsy Behav 2000; 1: 396-405.
55. Mauro AM, Bumprezzi C, Morresi S, et al. Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine. J Neurooncol 2007; 81: 279-285.
56. Albani F, Bisulli F, Barzaghi M, et al. Multicentre observational study evaluating immediate and progressive switching from carbamazepine to oxcarbazepine in patients with epilepsy. Funct Neurol 2007; 22: 111-115.
57. Azar NJ, Wang L, Song Y, Abou-Khalil BW. Temporal pattern of oxcarbazepine and phenytoin withdrawal seizures during epilepsy monitoring. Epilepsy Res 2008; 79: 78-83.